Exploratory Study to Evaluate the Effect of Uninterrupted Anticoagulants in Catheter Ablation Procedure for Non-valvular Atrial Fibrillation - Comparison between Rivaroxaban and Warfarin -

Trial Profile

Exploratory Study to Evaluate the Effect of Uninterrupted Anticoagulants in Catheter Ablation Procedure for Non-valvular Atrial Fibrillation - Comparison between Rivaroxaban and Warfarin -

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Cerebral infarction; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms ASCERTAIN Study
  • Most Recent Events

    • 02 Jan 2017 Status changed from active, no longer recruiting to completed according to the results presented at the 89th Annual Scientific Sessions of the American Heart Association.
    • 16 Nov 2016 Primary endpoint (The incidence of asymptomatic cerebral infarction caused by catheter ablation) has not been met,according to the results presented at the 89th Annual Scientific Sessions of the American Heart Association.
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top